Sustain Drug Release Company UroGen Submits New Drug Application to FDA
Kite Pharma founder Arie Belldegrun is the chairman of Israel-based UroGen, which focuses mainly on cancer treatment and urinary tract infections
UroGen raised $58 million when it listed on Nasdaq in May 2017, at a post-IPO company value of $155 million. Kite Pharma founder Arie Belldegrun sits as UroGel’s chairman of the board and is also an investor.
UroGen is currently trending down.